Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Braskem Q4 2025 2025 Earnings Call - EBITDA Down 49%, Leverage at 14.74x, $2.1bn Cash as Restructuring Looms
Braskem delivered a bruising set of results for 2025, with recurring consolidated EBITDA plunging to $557 million, down 49% versus 2024, and Q4 recurring EBITDA of $109 million. The industrywide overs...
- Recurring consolidated EBITDA for Q4 2025 was $109 million, and recurring consolidated EBITDA for FY2025 was $557 million, a 49% decline versus 2024.
- Operating cash generation in Q4 was approximately $13 million, while the company reported operating cash consumption of $246 million for the year in USD terms and BRL 1.4 billion in local currency terms.
- Corporate cash at 31 Dec 2025 totaled about $2.1 billion, which includes a $1.0 billion standby facility drawn in October that matures in December 2026.
- +12 more takeaways
Carnival Corporation First Quarter 2026 Earnings Call - PROPEL launched: big returns target and $2.5bn buyback, even as fuel spike dents 2026
Carnival rode strong demand into Q1, reporting record revenues, higher yields and a $275 million net income, while customer deposits hit a near $8 billion first quarter high. Management used the momen...
- Q1 2026 delivered record first quarter revenues, net yields up 2.7% year over year, and net income of $275 million, about 55% higher than prior year.
- Customer deposits reached almost $8 billion in Q1, a new first quarter record and roughly 10% higher than last year, reflecting earlier guest engagement and heavier pre-cruise sales.
- Bookings for current year sailings rose roughly 10% year over year, leaving nearly 85% of 2026 capacity already on the books and future-year bookings also at a first quarter record.
- +12 more takeaways
Legence Q4 2025 Earnings Call - Record revenue and backlog driven by data center fabrication and Bowers acquisition
Legence closed 2025 with a blowout quarter, reporting Q4 revenue of $738 million, up 35% year over year, and record backlog and awards of $3.7 billion, up nearly 50% year over year. Management says mo...
- Q4 2025 revenue $738 million, up 35% year over year, quarter was well ahead of prior guidance.
- Full year 2025 revenue $2.6 billion, up 22%; adjusted EBITDA for FY2025 $299 million, up 30% year over year.
- Q4 adjusted EBITDA $87 million, up 53% year over year; adjusted EBITDA margin improved ~140 basis points to 11.8% in the quarter.
- +16 more takeaways
Southland Q4 2025 Earnings Call - Sureties step in after $136M Washington State Convention Center charge
Southland reported a brutal Q4 and full-year 2025, with revenue for the quarter of $104 million and a $193 million gross loss driven by legacy-project writedowns. The headline charge was a $136 millio...
- Q4 revenue was $104 million, but that figure includes a $92 million revenue reversal tied to legacy dispute adjustments.
- Reported Q4 gross loss was $193 million, sharply worse than prior year Q4 gross profit of $8 million.
- A $136 million adverse trial ruling on the Washington State Convention Center (WSCC) project was the primary driver of the charge, including an $85 million judgment, $40 million reversal of an expected recovery, $6.4 million retention, and $4.8 million related to a sanctions order as described by management.
- +11 more takeaways
Autolus Therapeutics Q4 2025 Earnings Call - Strong first-year AUCATZYL sales ($74M) validate launch but scaling, margins and cash runway become the next test
Autolus closed 2025 with a credible first commercial year for AUCATZYL, recognizing $74.3 million in net product revenue and activating 67 treatment centers. Management reiterated 2026 guidance of $12...
- AUCATZYL first full year revenue in 2025 was $74.3 million, with Q4 product revenue of $23.3 million and total Q4 revenue $24.3 million including a $1 million Moderna milestone.
- Company reiterates 2026 net revenue guidance of $120 million to $135 million and targets more than 80 activated centers by year-end 2026, up from 67 at end-2025.
- Autolus expects to shift to positive gross margins in 2026, driven by higher volumes that spread fixed costs and by operational improvements to lower variable cost per batch.
- +11 more takeaways
Sanuwave Q4 2025 Earnings Call - Record Quarter Despite CMS Audit Shock, Pivot to Resellers
Sanuwave closed 2025 on a high note, posting record Q4 revenue and system placements even as a brutal CMS reset on skin substitutes rippled through the wound-care ecosystem. Management says UltraMIST ...
- Q4 2025 revenue hit an all-time quarterly high of $13.4 million, up 30% year over year, and adjusted EBITDA was $4.8 million, representing 36% of revenue.
- Full-year 2025 revenue was $44.1 million, a 35% increase versus 2024, and full-year adjusted EBITDA rose 89% to $13.6 million from $7.2 million.
- System placements accelerated, with 624 UltraMIST systems sold in 2025 versus 374 in 2024, and Q4 2025 alone accounted for a record 255 system sales.
- +13 more takeaways
Kopin Corporation Fourth Quarter 2025 Earnings Call - Government shutdown dents Q4, $56M capital and MicroLED pipeline position Kopin for a 2026 rebound
Kopin framed Q4 2025 as a hiccup, not a trend. Revenues plunged to $8.4 million from $14.6 million the prior year, with management attributing the shortfall to deeper-than-expected procurement delays ...
- Q4 2025 revenue fell to $8.4 million, down from $14.6 million in Q4 2024, management attributes the decline mainly to procurement and milestone recognition delays from the U.S. government shutdown.
- Kopin completed a $56 million private placement in 2025, which management says removed going concern doubt and materially strengthened the balance sheet.
- Year-end backlog was reported around $37 million, and management expects to book additional tens-of-millions of dollars in orders within the next 6 to 8 weeks.
- +12 more takeaways
SBC Medical Group Holdings Q4 FY2025 Earnings Call - Profitability Normalizes After Restructuring; AI and Longevity Become Growth Playbooks
SBC reported a messy but familiar reset. Clinic-level metrics show early signs of recovery, led by a sharp Q4 rebound in average revenue per customer to $316, while consolidated revenue fell as the co...
- Clinic footprint and customer base: SBC operates 283 locations and served 6.63 million customers on a trailing twelve month basis as of December 2025.
- Clinic revenue vs consolidated revenue: Company reported total clinic revenue of $1,163 million for the year, a 2% increase year over year, while consolidated full year revenue was stated as $174 million, down 15% year over year due to 2024 restructuring and April 2025 fee changes, suggesting different scopes or reporting layers that need clarification.
- Q4 unit economics rebound: Average revenue per customer reversed prior declines and rebounded to $316 in Q4, an 11% year-over-year increase, which management called an inflection in underlying momentum.
- +11 more takeaways
Super League Gaming Q4 2025 Earnings Call - Misfits Ads deal positioned as the fast track to cash EBITDA by year-end 2026
Super League says 2025 was a reset year, and the numbers show a company that has cut costs, cleaned its balance sheet, and is now trying to buy its way to scale. Management reported its strongest reve...
- Company says Q4 2025 was the strongest revenue quarter of the year, revenue up 32% versus Q3 2025 and roughly level with Q4 2024.
- Super League ended 2025 debt-free, with more than $14 million in capital as of December 31, and removal of the going-concern language from the auditor’s report.
- Management reports full-year gross margin improved to 40% in 2025 from 38% in 2024, and believes sustainable gross margin sits in the 40%–45% range.
- +11 more takeaways
The Metals Company Q4 2025 Earnings Call - U.S. permitting momentum fuels Brownsville processing push and Hidden Gem commissioning timeline
The Metals Company used this update to push a single narrative, regulatory clarity equals commercial runway. Management flagged a strategic pivot to the U.S. Deep Seabed Hard Mineral Resources Act, a ...
- Company pivoted from ISA to U.S. regulatory regime under the Deep Seabed Hard Mineral Resources Act (DSHMRA) and President Trump�s executive order, positioning the U.S. as the primary jurisdiction for its development.
- TMC submitted the first consolidated NOAA application under the revised permitting process, which was deemed substantially compliant; management expects grant of the commercial recovery permit within 12 months.
- Consolidated application expands expected commercial recovery area from 25,000 sq km to approximately 65,000 sq km.
- +16 more takeaways